Nurix Therapeutics News and Activities

Presence

Nurix Therapeutics develops targeted protein modulation medicines for cancer and immune disorders. It provides drug discovery, clinical development, and research partnerships for patients, healthcare providers, and pharmaceutical companies.

Nurix Therapeutics products and services overview:

Cancer therapies
Immune disorder drugs
Protein degrader platforms
Drug discovery services
Research partnerships

Revenue: ~$95 million

Employees: 310

Headquarters: San Francisco, United States (USA)

Nurix Therapeutics is one of the...

Nurix Therapeutics is a company listed under the stock ticker NRIX (US).

Executives

View the org chart displaying its 39 main executives

Most searched biographies at Nurix Therapeutics

Popular executive movements at Nurix Therapeutics

Laura Resnansky has joined the company as Senior Vice President, Development Operations (posted on June 18 2026).
Wes Burwell has joined the company as Chief Human Resources Officer (posted on June 18 2026).
Roger Dansey has joined the company as Director (posted on November 10 2025).

Create your alert
to follow the executive moves at Nurix Therapeutics.

Biotechnology

Nurix Therapeutics has 2,424 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).

Popular M&A news in Biotechnology

The new name of EG 427 is Cyllene Therapeutics. (posted on July 10 2026).
Opthea will change its company name to Ceryvyn Therapeutics on Jul 9, 2026. (posted on July 9 2026).
Tissium has just announced a $60 Million fundraising (posted on July 8 2026).